A Deep Dive into the Insider Trading: Citigroup Inc. (C), AbbVie Inc. (ABBV)

Looking at top Wall Street opinions, Citigroup Inc. (NYSE: C) has recently made its way into the research list of Keefe Bruyette – signaling that their analyst’s rating adjustment is noteworthy. This stock was upgraded to a rating of Outperform in the eyes of Keefe Bruyette, whereas its previous rating was Mkt Perform in the eyes of Keefe Bruyette, as reported on Friday, July 26th, 2019. Another heavy-hitting research note was published by Goldman on Thursday May 30th, 2019, with this firm upgrading C to an updated rating of Buy from its previous rating of Neutral. In the past six months and three months of trading, shares of Citigroup Inc. (C) have moved by 3.45% and -0.66%, respectively.

Brokerage Updates Related to Citigroup Inc. (C) Stock

This publicly-traded organization generated losses of -2.14% over the last 5 sessions. Right now, this stock is the subject of 28 analysts’ evaluations, who – on average – have given this company’s shares a Strong Buy rating. Of the latest market expert opinions, 1 have given an underperform rating, 0 has given a sell rating, and 12 have given a rating of Buy or better. Based on the 28 stock market experts following this company, the average 12-month price target is $83.40. Moreover, individual price targets range between $52.00-$109.00. With its recent move to $81.00, we can see that these firms project this stock will loss by -7.73% in one year.

Updates from Citigroup Inc. (C) SEC Form 4

This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.20% rise since the beginning of the calendar year.

Citigroup Inc. (NYSE:C) Results in the Pipeline

The next scheduled release of financial results for Citigroup Inc. will be for the Jun-19 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $1.80. In the same vein, they expect sales for the quarter to amount to $18,494.80 million.

Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $18,758.00 million in revenue alongside EPS at $1.83. On average, the analyst projection was calling for $18,576.00 million with $1.87 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $17,124.00 million, with earnings per share ending up at $1.61.

AbbVie Inc. (NYSE:ABBV) experienced a gain of 0.74% from the closing price in the previous trading day. That boost the price to $65.01 per share, as observed on January 1st, 1970, at a time when the total trading volume reached 7,099,284 shares of stock – compared to the typical average of 10.11M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $85.25.

Pricing Indications for AbbVie Inc. (ABBV)

This organization has had a price-to-earnings ratio of 23.43 in the last year. Meanwhile, it gained 71.33 from its observable 50-day simple moving average. Right at this moment, the per-share value is -18.65% lower than the mean per-share price over the last 200 days in the market.

AbbVie Inc. (NYSE:ABBV) In-Depth Brokerage Insights

We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 2 have a Buy rating, 2 have an outperform rating, while 9 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 2.50, based on information from Thomson Reuters.

ABBV Stock Value Potential

In trading activity as of late, this stock’s value was 79.84 up from its 200 day moving average, while also -9.14% down when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $74.00-$90.00. The market value for the entire organization reached 96.21B. In the last trading session, the price ended the day at $64.53. The institutional holdings related to this organization account for 0.10%, and the Beta factor is now 0.93. This company’s RSI (Relative Strength Index) managed to hit 33.68.

AbbVie Inc. (NYSE:ABBV) Analyst Points of Focus

AbbVie Inc. (ABBV) has found itself inside of Wolfe Research’s research list, so their analyst rating adjustment is worth taking note of. This stock was upgraded to Peer Perform, compared to its previous rating of Underperform by Wolfe Research, as garnered from a news report on Thursday June 27th, 2019. An additional helpful research note was sent out by SVB Leerink’s on Wednesday June 26th, 2019. The brokerage decided to upgrade ABBV to Outperform from its previous rating of Mkt Perform.